Oramed Pharmaceuticals Inc. (OJU1)
XMUN 
Summary
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group.
Oramed Pharmaceuticals Inc. (OJU1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oramed Pharmaceuticals Inc. ever had a stock split?
Oramed Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nadav Kidron CEO | XMUN Exchange | US68403P2039 ISIN |
| US Country | 13 Employees | 16 Jan 2026 Last Dividend | 23 Jan 2013 Last Split | 21 Apr 2006 IPO Date |
Overview
Oramed Pharmaceuticals Inc. is at the forefront of pharmaceutical innovation, focusing on developing advanced solutions for managing diabetes and creating novel methods for oral delivery of polypeptides. Established in 2002 and based in New York, the company is pioneering in its approach to tackle some of the most challenging health issues. With a strong foundation in research and development, Oramed is dedicated to improving patient care and outcomes through its groundbreaking work in oral drug delivery systems and therapeutics.
Products and Services
- ORMD-0801 - Oral Insulin Capsule
This flagship product of Oramed Pharmaceuticals Inc. is designed to revolutionize diabetes treatment by providing an oral insulin solution, currently in phase III clinical trials for diabetes patients. It's also being researched in a phase II clinical trial targeting non-alcoholic steatohepatitis (NASH), showcasing its potential versatility in handling different medical conditions.
- ORA-D-013-1 and ORA-D-013-2 - Type 2 Diabetes Treatment
Both ORA-D-013-1 and ORA-D-013-2 have successfully completed phase II clinical trials. These products represent Oramed's commitment to expanding its portfolio in the treatment of type 2 diabetes, providing innovative therapeutic solutions to address this widespread healthcare challenge.
- Licensing Agreements with Oravax Medical Inc.
Oramed has entered into strategic license agreements with Oravax Medical Inc. for the commercialization of oral vaccines targeting COVID-19 and other novel coronaviruses. This partnership underscores Oramed’s dedication to addressing global healthcare crises through inventive approaches and broadens its impact beyond diabetes care.
